Navigation Links
High-Risk Women May Often Avoid Using Tamoxifen
Date:12/4/2009

Armed with knowledge of risks, many hesitate to take breast cancer drug, study finds

FRIDAY, Dec. 4 (HealthDay News) -- Worries about side effects are a major reason why only 6 percent of American women at high risk for breast cancer are willing to take the drug tamoxifen to prevent the disease, a new study finds.

In an effort to inform women about the risks and benefits of tamoxifen, researchers at the University of Michigan Comprehensive Cancer Center created a decision aid, which was tailored to the health history of each of the 632 women in the study.

"That means, when women read this decision aid, they learned about how the drug was likely to affect them given their age, race, breast cancer history and medical history," study author Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a research investigator at the VA Ann Arbor Healthcare System, said in a university news release.

The researchers found that the decision aid helped inform the women about the risks and benefits of tamoxifen, with 63 percent correctly answering at least five of the six questions about the drug and 41 percent getting all six questions right.

However, although the women apparently achieved a high level of understanding about the risks and benefits of tamoxifen therapy, only 29 percent said they were likely to look for more information about the drug, 29 percent said they'd talk to their doctor about it and only 6 percent said they were likely to take tamoxifen. When questioned about the drug again three months later, fewer than 1 percent of the women had started taking the drug and fewer than 6 percent had sought more information or talked to their doctor about tamoxifen.

Eighty percent of the women in the study said they were worried about the drug's side effects, which can include hot flashes, sexual problems and, in rare cases, blood clots, cataracts or endometrial cancer, the study authors noted.

"Experts have bemoaned the dearth of women taking these pills, worried that word has not gotten out about tamoxifen's ability to prevent breast cancer in high-risk women. Our study shows that even when the word does get out, most women are too concerned about the pills' side effects to want to take it," senior author Dr. Peter Ubel, a professor of internal medicine and director of the University of Michigan's Center for Behavioral and Decision Sciences in Medicine, said in the news release.

The study was released online in advance of publication in an upcoming print issue of the journal Breast Cancer Research and Treatment.

More information

The U.S. National Cancer Institute has more about tamoxifen.



-- Robert Preidt



SOURCE: University of Michigan, news release, Dec. 3, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds
2. Mammograms May Boost Cancer Risk in High-Risk Women
3. Mammography may increase breast cancer risk in some high-risk women
4. Mammography May Increase Breast Cancer Risk in Some High-Risk Women
5. Should noninvasive ventilation be considered a high-risk procedure during an epidemic?
6. MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral Regurgitation
7. Study finds promise in combined transplant/vaccine therapy for high-risk leukemia
8. NCCN Stresses Importance of PSA Testing in High-Risk Men
9. New drug for children with high-risk leukemia
10. Barriers to diabetes care include restaurants and high-risk lifestyles, says international review
11. Salt Boosts Blood Pressure in High-Risk Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: